Medifocus Inc. (MDFZF) 0.1250 $MDFZF
Medifocus, Inc. Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014
Marketwire - Wed Jul 30, 8:54AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a revenue generating biotechnology company using focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for fiscal year and the fourth fiscal quarter ending March 31, 2014. Sales from its Prolieve(R) Thermodilatation System, reached $5,383,973 for the fiscal year ended March 31, 2014, representing an increase of 198% from the prior year. In July 2012, Medifocus acquired the Prolieve(R) business from Boston Scientific Corporation and recorded revenues of $1,805,969 from Prolieve for the Fiscal Year ended March 31, 2013. The net loss before other charges for the year was $5,222,429, a decrease of $374,043, or 7%, from the previous year primarily due to the revenue growth.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Pr
Marketwire Canada - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Products"
Marketwire - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"
Marketwire Canada - Tue Jul 08, 11:02AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com
Medifocus Inc. Announces Extension of Warrants
Marketwire - Wed Jun 18, 1:29AM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference
Marketwire Canada - Tue May 27, 9:21AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that, to increase investor's awareness and Medifocus, Inc.'s visibility in the U.S. capital markets, it will present at both the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference in New York City.
Medifocus Inc. To Present At The Third Annual Marcum MicroCap Conference
PR Newswire - Thu May 22, 11:01AM CDT
Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS) announced today that John Mon, Chief Operating Officer will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014
Marketwire - Wed Jul 30, 8:54AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a revenue generating biotechnology company using focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for fiscal year and the fourth fiscal quarter ending March 31, 2014. Sales from its Prolieve(R) Thermodilatation System, reached $5,383,973 for the fiscal year ended March 31, 2014, representing an increase of 198% from the prior year. In July 2012, Medifocus acquired the Prolieve(R) business from Boston Scientific Corporation and recorded revenues of $1,805,969 from Prolieve for the Fiscal Year ended March 31, 2013. The net loss before other charges for the year was $5,222,429, a decrease of $374,043, or 7%, from the previous year primarily due to the revenue growth.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Pr
Marketwire Canada - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Products"
Marketwire - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"
Marketwire Canada - Tue Jul 08, 11:02AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com
Medifocus Inc. Announces Extension of Warrants
Marketwire - Wed Jun 18, 1:29AM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference
Marketwire Canada - Tue May 27, 9:21AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that, to increase investor's awareness and Medifocus, Inc.'s visibility in the U.S. capital markets, it will present at both the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference in New York City.
Medifocus Inc. To Present At The Third Annual Marcum MicroCap Conference
PR Newswire - Thu May 22, 11:01AM CDT
Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS) announced today that John Mon, Chief Operating Officer will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
